Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)

  • End date
    Dec 31, 2026
  • participants needed
  • sponsor
    Peking University First Hospital
Updated on 18 May 2022
glomerular filtration rate


This study aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. It will enroll approximately 5000 pre-dialysis chronic kidney disease patients aged between 18 and 74 years in mainland China and follow-up for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at baseline and annually. The principal clinical outcomes of the study consist of renal disease events, cardiovascular events, and death.


The study is a multicenter prospective cohort study, aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. The study will establish a baseline cohort of 5000 Chinese pre-dialysis chronic kidney disease patients, who will be followed up until death or dropout or starting renal replacement therapy. The follow-up will be conducted for at least 5 years. Their clinical information and biomaterials will be collected at baseline and then annually during follow-up.

The baseline visit includes the following items: detailed demographics; socioeconomic and health care services information; medical and family history; medication history; and questionnaires concerning quality of life, health behaviors, depressive and anxiety symptoms, cognitive function, and physical activity. Anthropometric measures (height, weight, waist circumference, hip circumference, resting blood pressure, heart rate, grip strength, and 15-feet measured walk) will also be collected. The laboratory parameters of chemistry test, intact parathyroid hormone, 24-hour urine electrolytes, protein creatinine ratio, and albumin creatinine ratio should also be collected for each participant and measured in the central laboratory. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection.

The principal clinical outcomes of the study can be broadly categorized as renal disease events, cardiovascular events, and death. Renal disease events include the incident end stage renal disease or significant loss of renal function.Cardiovascular events include acute myocardial infarction, unstable angina, hospitalization for congestive heart failure, incident serious cardiac arrhythmia, cerebrovascular events, and peripheral vascular diseases. Death is further clarified as cardiac, cerebrovascular, renal, others, or unknown.

Condition Renal Insufficiency, Chronic
Treatment Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Clinical Study IdentifierNCT03041987
SponsorPeking University First Hospital
Last Modified on18 May 2022


Yes No Not Sure

Inclusion Criteria

Participants should meet the following criteria of enrollment according to their etiology
of nephrology
For glomerular nephrology patients, the estimated glomerular filtration rate (eGFR)
should be ≥15 ml/minute per 1.73m(2)
For diabetic nephrology patients, the defining eligibility was 15 ml/minute per
73m(2) ≤eGFR<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with
nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or
urinary albumin creatinine ratio (ACR) ≥2 000 mg/g or corresponding values of urine
dipstick test or urinary protein creatinine ratio (PCR)
For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per
73m(2)≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment

Exclusion Criteria

Participants meeting even one of the listed items should be excluded
NYHA Class III or IV heart failure
Self-reported or known diagnosis of HIV infection and/or AIDS
Isolated hematuria
Self-reported or known diagnosis of cirrhosis
Pregnant or breast-feeding women
Chronic kidney disease caused by systemic inflammatory illness or autoimmune disease
Malignancy treated with chemotherapy within last 2 years
such as lupus erythematosus
Renal or other transplantation
Treated with immunosuppressive agents in the preceding 6 months to treat renal or
Hereditary kidney disease
Participation in interventional clinical trial
immune disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note